Gowthami Morey Arepally, MD

Professor of Medicine
Associate Professor of Pathology
Professor of Pathology
Campus mail Duke Box 3486, Durham, NC 27710
Phone (919) 668-3696
Email address arepa001@mc.duke.edu

Gowthami M. Arepally, M.D. is a Professor of Medicine in the Division of Hematology at Duke University Medical Center.  Her clinical interests are in immune thrombocytopenias, thrombotic disorders, and complement-mediated diseases.  Dr. Arepally’s long-standing research program investigates the immune pathogenesis of heparin induced thrombocytopenia (HIT).  Current laboratory efforts focus on the role of complement activation in antibody production and thrombosis in HIT, studies of complement inhibitors for immune-complex mediated diseases and diagnostic biomarkers of platelet activation.  

Education and Training

  • Fellow in Hematology-Oncology, Medicine, University of Pennsylvania, 1993 - 1997
  • Chief Medical Resident, Medicine, Emory University, 1992 - 1993
  • Medical Resident, Medicine, Emory University, 1989 - 1992
  • M.D., Vanderbilt University, 1989

Publications

Schmitz, Robin, Zachary W. Fitch, Paul M. Schroder, Ashley Y. Choi, Miriam Manook, Janghoon Yoon, Mingqing Song, et al. “C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates.” Nat Commun 12, no. 1 (September 15, 2021): 5456. https://doi.org/10.1038/s41467-021-25745-7.

PMID
34526511
Full Text

Dhoot, Roshni, Aman Kansal, Chauncy Handran, Tarek Haykal, James Ronald, Matthew Kappus, Gowthami M. Arepally, Mark Graham, and John J. Strouse. “Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy.” Am J Hematol 96, no. 9 (September 1, 2021): 1180–82. https://doi.org/10.1002/ajh.26258.

PMID
34057234
Full Text

Barbour, T., M. Scully, G. Ariceta, S. Cataland, K. Garlo, N. Heyne, Y. Luque, et al. “Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.” Kidney International Reports 6, no. 6 (June 1, 2021): 1603–13. https://doi.org/10.1016/j.ekir.2021.03.884.

Full Text

Rondeau, Eric, Marie Scully, Gema Ariceta, Tom Barbour, Spero Cataland, Nils Heyne, Yoshitaka Miyakawa, et al. “Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.” Kidney Int 99, no. 5 (May 2021): 1244. https://doi.org/10.1016/j.kint.2021.03.008.

PMID
33892867
Full Text

Rondeau, Eric, Marie Scully, Gema Ariceta, Tom Barbour, Spero Cataland, Nils Heyne, Yoshitaka Miyakawa, et al. “Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.” Kidney Int 98, no. 6 (December 2020): 1621. https://doi.org/10.1016/j.kint.2020.11.001.

PMID
33276869
Full Text

Johnston, Ian, Amrita Sarkar, Vincent Hayes, Gavin T. Koma, Gowthami M. Arepally, Junmei Chen, Dominic W. Chung, et al. “Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation.” Blood 135, no. 15 (April 9, 2020): 1270–80. https://doi.org/10.1182/blood.2018881607.

PMID
32077913
Full Text

Pages